Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Omalizumab
Therapeutic Area : Pulmonary/Respiratory Diseases
Study Phase : Phase I
Sponsor : Alvotech
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Details : Under terms of the agreement, Alvotech will receive exclusive global rights for AVT23, a proposed biosimilar to Xolair. BiosanaPharma and Alvotech will jointly further the development of AVT23, which is currently in late-stage development.
Product Name : Undisclosed
Product Type : Antibody, Unconjugated
Upfront Cash : Undisclosed
February 02, 2022
Lead Product(s) : Omalizumab
Therapeutic Area : Pulmonary/Respiratory Diseases
Highest Development Status : Phase I
Sponsor : Alvotech
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Reset All
